Bristol-Myers Squibb $BMY announced on Tuesday that it would assess the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers. Opdivo, which competes with Merck & Co's Keytruda, belongs to a costly new class of medicines branded PD-1 checkpoint inhibitors that work by taking the brakes off the immune system.